Yao Yu: Happy to share our work on Stereotactic radiosurgery with concurrent Antibody Drug Conjugates
Yao Yu, Radiation Oncologist at Memorial Sloan Kettering Cancer Center, shared on X/Twitter:
“Happy to share our work on Stereotactic radiosurgery (SRS) with concurrent Antibody Drug Conjugates (ADCs), now out in JAMA Oncology! In this study, led by Emily Lebow, we investigated the risk of symptomatic radiation necrosis for patients receiving SRS in brain metastases. ADCs included T-DXd (Trastuzumab deruxtecan), T-DM1 (Trastuzumab emtansine) and SG (Sacituzumab govitecan).
The study included 98 patients and 564 individual brain metastases treated at Memorial Sloan Kettering. We tracked information on brain metastasis volume, ADC timing, and all courses of prior and subsequent radiotherapy. Concurrent ADC was defined as ADC <= 3 weeks before SRS or < 1 week after SRS.
The overall risk of symptomatic radiation necrosis was 8.5% for the entire cohort, but concurrent ADC was associated with much higher risk (SHR 4.01) on univariable analysis. This risk was independent of volume (SHR 1.14 /cc) and prior RT (SHR 2.99).
The absolute risk of symptomatic radiation necrosis after SRS and concurrent ADC was low for small brain metastases, but increased rapidly with volume. Similar effects were observed across ADCs.
We hope teams treating brain metastases will find this useful when counseling and selecting patients for SRS. More to come from our team!”
For the article click here.
Source: Yao Yu/Twitter
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023